Last Price
52 Week Range
$3.76 - $46.80
Next Earnings Date
Nov 04 2025 (Estimate)
Next Earnings Date
Nov 04 2025 (Est.)
Last Price
Market Cap | $46.57M |
EV | $-69.50M |
Shares Outstanding | 6.15M |
Beta | 2.78 |
Analyst Rating | BUY |
Analyst Target Price | $90.33 |
P/E 2025E | - |
P/Revenue 2025E | 20.35x |
Revenue | -3.30% |
EPS | 36.20% |
Operating Cash Flow | 11.30% |
Free Cash Flow | 11.50% |
Revenue | -14.70% |
EPS | 31.40% |
Operating Cash Flow | - |
Free Cash Flow | -3.90% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | -2024.17% |
ROE 2025E | - |
ROCE 2024 | -415.84% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Aligos Therapeutics, Inc.
ALGS
Sector
Healthcare
Industry
Biotechnology
CEO
Blatt, Lawrence
Employees
70
Website
aligos.comIPO Date
2020-10-16
Headquarters
One Corporate Drive, 2nd Floor, South San Francisco, California, 94080, United States
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.